# Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

> **NCT00973271** · PHASE3 · WITHDRAWN · sponsor: **Essentialis, Inc.**

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** 290 mg DCCR
- **DRUG:** 435 mg DCCR
- **DRUG:** 135 mg fenofibric acid
- **DRUG:** Placebo
- **DRUG:** atorvastatin

## Key facts

- **NCT ID:** NCT00973271
- **Lead sponsor:** Essentialis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Did not continue with development of DCCR in Very High Triglycerides
- **Last updated:** 2016-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00973271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00973271, "Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00973271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*